Form 4: Enveric Director Receives Stock Grant Amid Reverse Splits

Enveric Biosciences Director Frank Pasqualone was granted 7,633 restricted common shares, with reported holdings adjusted for two recent reverse stock splits.

Summary

• Director Frank Pasqualone acquired 7,633 shares of Enveric Biosciences, Inc. common stock on December 23, 2025.
• These shares were granted as restricted stock under the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended.
• The shares will vest according to the terms and conditions of the Plan and the award agreement.
• Following this transaction, Pasqualone beneficially owns 7,904 shares directly.
• The reported share count reflects adjustments due to a 1-for-15 reverse stock split on January 29, 2025, and a 1-for-12 reverse stock split on October 28, 2025.

Sentiment

Score: 3

Explanation: While the restricted stock grant aligns director interests, the occurrence of two substantial reverse stock splits within a year (1-for-15 and 1-for-12) signals severe stock price underperformance and potential underlying operational or financial challenges for Enveric Biosciences, Inc.

Positives

• The grant of restricted stock to a director aligns management's interests with shareholders, incentivizing long-term performance.
• The grant is part of an established Long-Term Incentive Plan, indicating a structured approach to executive compensation.

Negatives

• The company underwent two significant reverse stock splits (1-for-15 and 1-for-12) within the year, which often signals a declining stock price and efforts to maintain listing requirements or improve market perception.
• The acquisition price of $0 for the restricted stock grant means no direct capital inflow to the company from this specific transaction.

Risks

• The occurrence of two reverse stock splits within a year (January 29, 2025, and October 28, 2025) indicates significant share price depreciation, which is a substantial risk factor for investors.
• Future dilution risk exists as restricted stock grants vest and become exercisable.

Future Outlook

The vesting of the granted restricted stock is contingent upon the terms and conditions of the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan and the reporting person's restricted stock award agreement, indicating future potential share issuance upon vesting.

Management Comments

• The restricted stock granted to the reporting person is pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended.
• Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.

Industry Context

This Form 4 filing is a routine disclosure of insider stock ownership changes. The occurrence of two reverse stock splits within a year for Enveric Biosciences, Inc. suggests the company has faced significant challenges in maintaining its share price, a trend sometimes seen in smaller biotechnology or early-stage pharmaceutical companies that may struggle with clinical trial results, funding, or market adoption.

Comparison to Industry Standards

• Granting restricted stock to directors is a common practice in the biotechnology and pharmaceutical industries to align long-term interests, similar to compensation structures at companies like Moderna or BioNTech for their executives and board members.
• However, two reverse stock splits within a year (1-for-15 and 1-for-12) are highly unusual and typically indicate severe stock price underperformance, far below industry benchmarks for stable, growing biotech firms. For example, a company like Amgen or Gilead Sciences would rarely, if ever, resort to such frequent and drastic reverse splits.

Corporate Governance

Stakeholder Impact

• Shareholders: The reverse stock splits have significantly reduced the number of outstanding shares, potentially impacting per-share metrics but also reflecting a loss of value. The stock grant could dilute future earnings per share upon vesting.
• Management/Directors: Frank Pasqualone benefits from the restricted stock grant, aligning his financial interests with the company's long-term performance.

Next Steps

• Vesting of the restricted stock will occur according to the terms of the 2020 Long-Term Incentive Plan and the award agreement.

Key Dates

Recommendation

The occurrence of two substantial reverse stock splits (1-for-15 and 1-for-12) within a single year is a strong negative indicator, suggesting severe stock price depreciation and potential fundamental issues with the company's business or financial health. While a director receiving a stock grant can be seen as an alignment of interests, it does not outweigh the significant red flags raised by the reverse splits. Investors should consider selling due to the clear signs of distress and poor performance.

Keywords

Enveric Biosciences, ENVB, Form 4, Insider Trading, Restricted Stock, Stock Grant, Director Compensation, Reverse Stock Split, Corporate Governance, Long-Term Incentive Plan